1421P EGFR Inhibition in EGFR-amplified Esophagogastric Cancer (EGC): Retrospective Global Experience

S. Maron, S. Moya,F. Morano,M. J. Emmett,U. Disel, S. Chalasani,G. Ku, P. M. Kasi,N. Uboha, S. Kato,K. Shitara,Y. Nakamura,J. Chao,J. Lee,Z. Wainberg,R. Petty,F. Pietrantonio,S. J. Klempner,D. V. Catenacci

Annals of oncology（2021）

引用 0|浏览20

暂无评分

摘要

Phase III evaluation of EGFR inhibition (EGFRi) in unselected EGC patients failed to demonstrate survival benefit. However, subset analyses identified improved outcomes in patients (pts) with EGFR-amplified EGC (6%). We therefore sought to evaluate the retrospective experience of EGFRi in EGFR-amplified EGC.

查看译文

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要